



Biological E. Limited

Celebrating Life Every Day

BE Pledges Its Offering of 5 Year Price Commitment to GAVI Graduated Countries

Hyderabad, India – January 27, 2015: Biological E. Limited (BE), the Hyderabad based Vaccines major has pledged its offering of a five year price commitment to GAVI (formerly Global Alliance for Vaccines and Immunization) graduated countries.

Ms. Mahima Datla, Managing Director, Biological E Limited, addressing the GAVI Pledging Conference in Berlin, Germany, on January 26, 2015 said that: “As a company, we are deeply committed to improving the quality of human life and make immunization our biggest health priority. However, it’s also true that access to immunisation still continues to be a challenge. We at Biological E. will strive to ensure affordability of vaccines is NOT one of the contributing factors, so that countries can focus on sustainability and on overcoming other obstacles that are coming in the way of reaching that last child. So, today, to further our support to GAVI’s mission, I am pleased to announce Biological E.’s offer of a 5-year price commitment to GAVI graduated countries. This commitment aims to ensure that graduated countries will have access to affordable prices that are comparable to GAVI-eligible ones.”

Addressing the conference **Dr. Seth Berkley, CEO, GAVI** said that: “It is encouraging to see vaccine manufacturers increasingly recognizing the importance of sustainable vaccine markets for developing countries. The commitments made today will help us make more vaccine doses available at a lower cost and will support countries as they move towards financing and sustaining their own immunisation programmes. This will lead to more children being protected and more deaths being averted.”

Biological E. Limited had earlier reduced the price of their Pentavalent vaccine by 30% in order to increase access as an example of a key market shaping collaborative outcome. Biological E. Limited together with the GATES Foundation, GAVI and UNICEF took the decision to reduce the price of Pentavalent vaccine. Ms. Mahima Datla had mentioned that it was contextual for Biological E. Limited to make this reduction in order to improve access of immunization because of the company’s *late* Chairman Mr. Vijay Kumar Datla’s vision of building a successful business that is also socially responsible and delivers value to shareholders and to the broader communities we live in.

Ms. Mahima Datla reiterated Biological E.'s commitment at the conference further by saying, "We are proud to support GAVI's replenishment effort and with this pledge, we commit to working with GAVI to give donors, country governments and ourselves the opportunity to save more lives. In our own humble capacity, we will continue to play our part in reducing inequities in access to vaccines, particularly in the countries that we together serve."

Ms. Angela Merkel, the Chancellor of Germany, hosted the pledging conference, which was attended by the several Heads of the States of European Union, GAVI members, CEOs of various vaccine manufacturing companies and other delegates.

About Biological E. Limited

Biological E. Limited, the first private sector biological products company in India and the first pharmaceuticals company in South India was established in 1953. Originally incorporated as Biological Products Private Limited, and launched by Dr. Vijay Kumar Datla, today, BE is a globally recognized vaccine manufacturer and has supplied over 2 Billion Doses of Vaccines till date all over the world. BE supplies several essential and lifesaving Vaccines and Pharmaceuticals to UN Agencies viz. UNICEF, PAHO, Many Global markets, and in India to the National Immunization program, various State Governments, PSUs, Indian Armed Forces and the domestic retail market. With a mission to improve health & survival of people and contribute to the societies BE serves by providing equitable access to quality vaccines and therapeutics. Biological E. Limited has a long and richly textured history of supporting public health programs in India for over five decades. Their portfolio of WHO prequalified vaccines include the 5-in-1 Pentavalent and a Japanese Encephalitis vaccine and their future offerings promise to be even more exciting.

For further information please contact: K. Vijay Amruth Raj, 8374077433